FDA classification of AI-enabled cervical cytology slide imaging systems

Current understanding

An FDA final rule classifies digital cervical cytology slide imaging systems with artificial intelligence algorithms as Class II medical devices subject to special controls. This de novo classification establishes a device-specific framework under which developers of future substantially equivalent systems can seek 510(k) clearance, subject to applicable controls and FDA review; it does not automatically clear those systems for clinical use.

Evidence log

Open questions

Related